Products

Zupanib Tablets (Pazopanib Tablets) – Product Description Zupanib Tablets contain Pazopanib, a prescription targeted anti-cancer medicine used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). It belongs to the tyrosine kinase inhibitor (TKI) class and works by blocking multiple enzymes involved in tumor growth and the formation of new blood vessels (angiogenesis), helping slow the progression of cancer. Zupanib is taken orally once daily, usually on an empty stomach, exactly as prescribed by the treating oncologist. It may be used as a single-agent therapy depending on the patient's diagnosis and treatment plan. Active Ingredient Pazopanib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (Kidney Cancer) Advanced Soft Tissue Sarcoma (STS) Other approved oncology indications as determined by the treating oncologist How It Works Pazopanib inhibits multiple tyrosine kinase receptors, including VEGFR, PDGFR, and c-KIT, reducing the formation of new blood vessels that supply tumors with oxygen and nutrients. This helps inhibit tumor growth and spread. Key Features Targeted therapy for advanced kidney cancer and soft tissue sarcoma Multi-targeted kinase inhibitor with anti-angiogenic activity Convenient once-daily oral tablet May help slow disease progression in eligible patients Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zupanib Tablets (Pazopanib) are prescription-only medicines and should be used only under the supervision of a qualified oncologist. Regular monitoring of liver function, blood pressure, thyroid function, and overall clinical status is recommended during treatment.

Zucarfil (Carfilzomib Injection 60 mg) – Product Description Zucarfil contains Carfilzomib 60 mg, a targeted anti-cancer medicine used for the treatment of relapsed or refractory multiple myeloma (RRMM). It belongs to the proteasome inhibitor class of medicines and works by irreversibly blocking the 20S proteasome, causing the accumulation of damaged proteins within cancer cells. This leads to cellular stress and programmed cancer cell death (apoptosis), helping slow disease progression. Zucarfil is supplied as a lyophilized powder for intravenous (IV) infusion and is administered by qualified healthcare professionals. It is commonly used in combination with medicines such as dexamethasone, lenalidomide, or daratumumab, depending on the patient's treatment regimen and clinical condition. Active Ingredient Carfilzomib 60 mg Dosage Form Lyophilized Powder for Injection (IV Infusion) Therapeutic Indications Relapsed Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma Combination Therapy Other approved indications as determined by the treating oncologist How It Works Carfilzomib selectively and irreversibly inhibits the 20S proteasome, preventing the breakdown of unwanted proteins inside cancer cells. The resulting protein buildup disrupts normal cell function, triggering apoptosis and reducing the growth of multiple myeloma cells. Key Features Targeted proteasome inhibitor for multiple myeloma Effective in relapsed and refractory disease Administered by intravenous infusion under specialist supervision Commonly used in combination with established myeloma therapies Manufactured according to stringent pharmaceutical quality standards Storage Store refrigerated at 2°C–8°C. Protect from light and do not freeze. Keep out of reach of children. Note: Zucarfil (Carfilzomib Injection 60 mg) is a prescription-only medicine and should be administered only by qualified healthcare professionals experienced in oncology. Patients should be monitored regularly for blood counts, kidney function, liver function, cardiac status, and infusion-related reactions throughout treatment.

Zucarb (Carboplatin Injection) – Product Description Zucarb contains Carboplatin, a prescription platinum-based chemotherapy medicine used in the treatment of various solid tumors, including ovarian cancer, lung cancer, head and neck cancer, and other malignancies. It belongs to the platinum-containing antineoplastic agents and works by damaging the DNA of cancer cells, preventing their growth and division, ultimately leading to cancer cell death. Zucarb is administered as an intravenous (IV) infusion by qualified healthcare professionals. It may be used alone or in combination with other chemotherapy medicines depending on the type and stage of cancer, as well as the patient's overall treatment plan. Active Ingredient Carboplatin Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Ovarian Cancer Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC) Head and Neck Cancer Endometrial Cancer Other solid tumors as recommended by the treating oncologist How It Works Carboplatin forms DNA cross-links within cancer cells, preventing DNA replication and repair. This disrupts cell division and triggers the death of rapidly dividing cancer cells, helping to slow or stop tumor growth. Key Features Platinum-based chemotherapy with proven clinical efficacy Effective against a wide range of solid tumors Suitable for use as monotherapy or combination chemotherapy Administered under specialist oncology supervision Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from excessive heat, freezing, and direct light. Keep out of reach of children. Note: Zucarb (Carboplatin Injection) is a prescription-only chemotherapy medicine and should only be administered by qualified healthcare professionals experienced in oncology. Regular monitoring of blood counts, kidney function, liver function, andelectrolyte levels is recommended throughout treatment.

Zovorin Injection (Leucovorin Calcium Injection 50 mg) – Product Description Zovorin Injection contains Leucovorin Calcium 50 mg, a folinic acid (reduced folic acid) medicine widely used in oncology and supportive cancer care. It is primarily administered to reduce the toxic effects of high-dose methotrexate therapy (leucovorin rescue) and to enhance the effectiveness of 5-Fluorouracil (5-FU) in the treatment of colorectal cancer. Leucovorin is also indicated for the treatment of certain folate deficiency conditions when oral therapy is not suitable. It is administered by qualified healthcare professionals through intravenous (IV) or intramuscular (IM) injection according to the prescribed treatment protocol. Active Ingredient Leucovorin Calcium 50 mg Dosage Form Sterile Injection Therapeutic Indications High-Dose Methotrexate Rescue Therapy Colorectal Cancer (in combination with 5-Fluorouracil) Folate Deficiency requiring injectable treatment Other approved indications as determined by the treating physician How It Works Leucovorin is an active form of folic acid that helps protect normal cells from the toxic effects of methotrexate without reducing its anti-cancer activity. When used with 5-Fluorouracil (5-FU), it enhances the binding of 5-FU to its target enzyme, improving the chemotherapy's effectiveness against cancer cells. Key Features Provides effective rescue following high-dose methotrexate therapy Enhances the efficacy of 5-Fluorouracil in colorectal cancer treatment Supports healthy folate metabolism Suitable for intravenous or intramuscular administration Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from light and excessive heat. Keep out of reach of children. Note: Zovorin Injection (Leucovorin Calcium 50 mg) is a prescription-only medicine and should be administered only under the supervision of qualified healthcare professionals. Treatment should follow established oncology protocols with appropriate clinical monitoring.

Zortemib (Bortezomib Injection) – Product Description Zortemib contains Bortezomib, a prescription targeted anti-cancer medicine used for the treatment of multiple myeloma and mantle cell lymphoma (MCL). It belongs to the proteasome inhibitor class of medicines and works by blocking the 26S proteasome, causing the accumulation of damaged proteins inside cancer cells. This disruption leads to cancer cell death and helps slow the progression of the disease. Zortemib is administered by qualified healthcare professionals as an intravenous (IV) or subcutaneous (SC) injection. It may be used alone or in combination with other anti-cancer medicines depending on the patient's diagnosis, treatment stage, and clinical condition. Active Ingredient Bortezomib Dosage Form Sterile Injection (Intravenous or Subcutaneous) Therapeutic Indications Multiple Myeloma Mantle Cell Lymphoma (MCL) Other approved hematologic malignancies as determined by the treating oncologist How It Works Bortezomib selectively inhibits the 26S proteasome, preventing the breakdown of proteins within cancer cells. This causes cellular stress, disrupts normal cell function, and triggers programmed cancer cell death (apoptosis), helping to control tumor growth. Key Features Targeted therapy for multiple myeloma and mantle cell lymphoma Proteasome inhibitor with a well-established role in hematologic oncology Can be administered by intravenous or subcutaneous injection May be used as monotherapy or in combination treatment regimens Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from moisture, excessive heat, and direct light. Keep out of reach of children. Note: Zortemib (Bortezomib Injection) is a prescription-only medicine and should be administered only under the supervision of a qualified oncologist. Regular monitoring of blood counts, liver function, kidney function, and neurological status is recommended during treatment.

Zoplide (Leuprolide Acetate Injection) – Product Description Zoplide contains Leuprolide Acetate, a prescription hormonal therapy medicine used to treat a variety of hormone-dependent cancers and endocrine disorders. It belongs to the gonadotropin-releasing hormone (GnRH) agonist class and works by reducing the production of testosterone in men and estrogen in women. Lowering these hormone levels helps slow the growth of hormone-sensitive cancers and manage certain gynecological and pediatric conditions. Zoplide is administered by a qualified healthcare professional as an injection at intervals determined by the prescribed treatment regimen. It is widely used in oncology and gynecology under specialist supervision. Active Ingredient Leuprolide Acetate Dosage Form Sterile Injection Therapeutic Indications Advanced Prostate Cancer Hormone Receptor-Positive Breast Cancer (selected patients) Endometriosis Uterine Fibroids Central Precocious Puberty (CPP) Other hormone-responsive conditions as recommended by a specialist How It Works Leuprolide Acetate initially stimulates and then suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This results in a significant reduction in testosterone and estrogen production, helping to slow the growth of hormone-dependent tumors and control disease symptoms. Key Features Effective hormonal therapy for hormone-sensitive cancers Long-acting GnRH agonist for sustained hormone suppression Used in oncology, gynecology, and pediatric endocrinology Administered under specialist medical supervision Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from excessive heat and direct light. Keep out of reach of children. Note: Zoplide (Leuprolide Acetate Injection) is a prescription-only medicine and should be administered only under the supervision of a qualified oncologist, gynecologist, or endocrinologist. Regular monitoring of hormone levels and overall clinical response is recommended throughout treatment.

Zomacta Tablets (Eltrombopag Olamine Tablets) – Product Description Zomacta Tablets contain Eltrombopag Olamine, a prescription medicine used to increase platelet counts in patients with certain blood disorders. It belongs to the thrombopoietin receptor agonist (TPO-RA) class and works by stimulating the bone marrow to produce more platelets, helping reduce the risk of bleeding associated with low platelet levels. Zomacta is commonly prescribed for patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to other treatments. It is also indicated for severe aplastic anemia (SAA) and for the treatment of thrombocytopenia associated with chronic hepatitis C, allowing eligible patients to initiate and maintain antiviral therapy under specialist supervision. Active Ingredient Eltrombopag Olamine Dosage Form Oral Tablets Therapeutic Indications Chronic Immune Thrombocytopenia (ITP) Severe Aplastic Anemia (SAA) Thrombocytopenia Associated with Chronic Hepatitis C Other approved indications as determined by the treating physician How It Works Eltrombopag binds to and activates the thrombopoietin (TPO) receptor on bone marrow cells, stimulating the production of platelets. Increased platelet counts help reduce the risk of bleeding in eligible patients with thrombocytopenia. Key Features Increases platelet production through TPO receptor stimulation Oral tablet for convenient daily administration Effective treatment option for chronic ITP and severe aplastic anemia Helps manage low platelet counts under specialist supervision Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zomacta Tablets (Eltrombopag Olamine) are prescription-only medicines and should be used only under the supervision of a qualified hematologist or physician. Regular monitoring of platelet counts, liver function, and complete blood counts is recommended during treatment.

Zolon (Oxaliplatin Injection) – Product Description Zolon contains Oxaliplatin, a prescription anti-cancer (chemotherapy) medicine used primarily for the treatment of colorectal cancer, including advanced and metastatic colon and rectal cancer. It belongs to the platinum-based chemotherapy class and works by damaging the DNA of cancer cells, preventing them from growing and dividing, which ultimately leads to cancer cell death. Zolon is administered as an intravenous (IV) infusion by qualified healthcare professionals. It is commonly used in combination with other chemotherapy medicines, such as 5-Fluorouracil (5-FU) and Leucovorin, as part of standard treatment regimens for colorectal cancer. Active Ingredient Oxaliplatin Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Colorectal Cancer Advanced Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Other oncology indications as determined by the treating oncologist How It Works Oxaliplatin forms DNA cross-links within cancer cells, preventing DNA replication and repair. This disrupts cell division and triggers the death of rapidly growing cancer cells, helping to slow disease progression. Key Features Platinum-based chemotherapy for colorectal cancer Proven component of standard combination chemotherapy regimens Administered under specialist medical supervision Suitable for use in hospital and oncology clinic settings Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from excessive heat and light. Keep out of reach of children. Tags Oxaliplatin Injection, Zolon Injection, Oxaliplatin IV Infusion, Colorectal Cancer Treatment, Colon Cancer Chemotherapy, Rectal Cancer Medicine, Platinum-Based Chemotherapy, Anti-Cancer Injection, Oncology Medicine, Metastatic Colorectal Cancer, Chemotherapy Drug, Generic Oxaliplatin, Cancer Treatment Injection, Hospital Oncology Medicine, Pharmaceutical Export India

Zixib Tablet (Axitinib Tablets) – Product Description Zixib Tablet contains Axitinib, a targeted anti-cancer medicine used primarily for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to the tyrosine kinase inhibitor (TKI) class of medicines and works by blocking vascular endothelial growth factor (VEGF) receptors, helping to reduce the blood supply that tumors need to grow and spread. Zixib is prescribed by oncologists for patients with advanced kidney cancer and may be used after prior systemic therapy or according to current treatment guidelines. The tablets are taken orally, with or without food, exactly as directed by the treating physician. Active Ingredient Axitinib Dosage Form Oral Tablets Therapeutic Indications Advanced Renal Cell Carcinoma (RCC) Advanced Kidney Cancer Other approved oncology indications as determined by the treating oncologist How It Works Axitinib selectively inhibits VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), preventing the formation of new blood vessels that supply nutrients and oxygen to tumors. This helps slow tumor growth and may reduce the spread of cancer. Key Features Targeted therapy for advanced kidney cancer Oral tablet for convenient administration Selective VEGF receptor inhibitor May be used alone or in combination with other oncology treatments Manufactured according to stringent pharmaceutical quality standards Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Note: Zixib Tablet (Axitinib) is a prescription-only medicine and should be used only under the supervision of a qualified oncologist. Regular monitoring of blood pressure, liver function, thyroid function, and other clinical parameters is recommended during treatmenT.

Zitomycin (Mitomycin Injection) – Product Description Zitomycin contains Mitomycin, a prescription anti-cancer (chemotherapy) medicine used in the treatment of various solid tumors, including gastric (stomach) cancer, pancreatic cancer, and bladder cancer. It belongs to the antitumor antibiotic class of chemotherapy agents and works by preventing cancer cells from growing and multiplying through DNA cross-linking, ultimately leading to cancer cell death. Mitomycin is administered by qualified healthcare professionals as an intravenous (IV) injection or, for certain bladder cancers, as intravesical therapy directly into the bladder. It may be used alone or in combination with other chemotherapy medicines depending on the patient's condition and treatment protocol. Active Ingredient Mitomycin Dosage Form Sterile Injection Therapeutic Indications Gastric (Stomach) Cancer Pancreatic Cancer Superficial Bladder Cancer (Intravesical Therapy) Other cancers as recommended by an oncologist How It Works Mitomycin acts by forming DNA cross-links, which prevent cancer cells from replicating and repairing their DNA. This inhibits cell division and promotes the destruction of rapidly growing cancer cells. Key Features Broad-spectrum chemotherapy agent Effective in selected gastrointestinal and bladder cancers Suitable for use as monotherapy or in combination chemotherapy Administered under specialist medical supervision Manufactured according to stringent pharmaceutical quality standards Storage Store as directed by the manufacturer. Protect from light and excessive heat. Keep out of reach of children. Note: Zitomycin (Mitomycin Injection) is a prescription-only chemotherapy medicine and should only be administered by qualified healthcare professionals experienced in oncology. Regular monitoring of blood counts, kidney function, and overall health is essential during treatment.

Zinotecan (Irinotecan Injection) – Product Description Zinotecan contains Irinotecan, a prescription anti-cancer (chemotherapy) medicine used to treat advanced or metastatic colorectal cancer and certain other cancers as recommended by an oncologist. It belongs to the topoisomerase I inhibitor class of chemotherapy drugs and works by interfering with the DNA replication process in rapidly dividing cancer cells, helping to slow or stop their growth. Zinotecan is administered as an intravenous (IV) infusion by trained healthcare professionals, either alone or in combination with other chemotherapy medicines such as 5-Fluorouracil (5-FU) and Leucovorin. Treatment schedules and dosage are determined by the patient's condition, body surface area, and overall treatment plan. Active Ingredient Irinotecan Hydrochloride Dosage Form Sterile Injection for Intravenous (IV) Infusion Therapeutic Indications Metastatic Colorectal Cancer Advanced Colorectal Cancer Other solid tumors, as determined by the treating oncologist How It Works Irinotecan inhibits the topoisomerase I enzyme, preventing cancer cells from repairing damaged DNA during cell division. This results in cancer cell death and helps reduce tumor growth. Key Features Effective chemotherapy for colorectal cancer Can be used as monotherapy or combination therapy Administered under medical supervision Manufactured according to stringent pharmaceutical quality standards Intended for hospital and oncology clinic use Storage Store according to the manufacturer's recommendations. Protect from excessive heat and light. Keep out of reach of children. Note: Zinotecan (Irinotecan Injection) is a prescription-only chemotherapy medicine and should be administered only by qualified healthcare professionals experienced in cancer treatment. Regular monitoring of blood counts and overall health is required throughout therapy.

Zimitib Cap (Imatinib 100 mg) – Product Description Zimitib Cap contains Imatinib 100 mg, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is primarily prescribed for the treatment of specific blood cancers and certain solid tumors by blocking abnormal proteins that promote the growth and multiplication of cancer cells. This targeted mechanism helps slow disease progression while preserving healthy cells more effectively than traditional chemotherapy. Active Ingredient Imatinib Mesylate 100 mg Dosage Form Oral Capsule Therapeutic Indications Zimitib Cap is prescribed for the treatment of: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Gastrointestinal Stromal Tumors (GIST) Myelodysplastic/Myeloproliferative Disorders (MDS/MPD) Hypereosinophilic Syndrome (HES) Dermatofibrosarcoma Protuberans (DFSP), as recommended by an oncologist. How It Works Imatinib inhibits specific tyrosine kinase enzymes, including the BCR-ABL protein, which is responsible for uncontrolled cancer cell growth. By blocking these enzymes, it slows or stops the proliferation of cancer cells and helps manage the disease. Key Features Targeted therapy for selected cancers Effective oral treatment option Helps control disease progression Suitable for long-term treatment under medical supervision Widely used in oncology treatment protocols Directions for Use Take exactly as prescribed by your oncologist. Swallow the capsule whole with a full glass of water. Take with food to minimize stomach irritation. Do not miss doses or discontinue treatment without consulting your physician. Storage Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Important Safety Information Common side effects may include: Nausea or vomiting Diarrhea Muscle cramps Swelling (fluid retention) Fatigue Skin rash Regular monitoring of blood counts and liver function is recommended during treatment. Contact your healthcare provider immediately if you experience severe swelling, unusual bleeding, fever, or signs of liver problems. Note: Zimitib Cap (Imatinib 100 mg) is a prescription-only medicine and should only be used under the supervision of a qualified oncologist.